97. Ulcerative colitis Clinical trials / Disease details

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04272307
(ClinicalTrials.gov)		May 14, 202014/2/2020MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.Inflammatory Bowel Diseases;Colitis;UlcerativeBiological: Blood samples;Procedure: Stool samples;Procedure: Colorectal biopsiesUniversity Hospital, BordeauxMcGill University Health Centre/Research Institute of the McGill University Health CentreRecruiting18 YearsN/AAll40France
2NCT04030676
(ClinicalTrials.gov)		July 17, 201919/7/2019QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative ColitisPlace of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)Cytomegalovirus InfectionsProcedure: Biopsies;Biological: Blood samplesCentre Hospitalier Universitaire de Saint EtienneNULLRecruiting18 YearsN/AAll196N/AFrance
3NCT03182166
(ClinicalTrials.gov)		November 21, 201729/5/2017Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose OptimizationPharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose OptimizationUlcerative ColitisDrug: Golimumab (Optimization);Diagnostic Test: Rectosigmoidoscopy;Biological: Blood samplesCentre Hospitalier Universitaire de Saint EtienneMerck Sharp & Dohme Corp.Completed18 YearsN/AAll51Phase 2France